Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in:

Open Access 18-11-2024 | Acute Myeloid Leukemia | Review

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead

Authors: Kalyan V. G. Nadiminti, Kieran D. Sahasrabudhe, Hongtao Liu

Published in: Journal of Hematology & Oncology | Issue 1/2024

Login to get access

Abstract

The AML treatment landscape has significantly changed in recent years with the approval of targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of FLT3 and IDH1/2 mutations. More importantly, approval of the combination of the BCl-2 inhibitor, venetoclax, and hypomethylating agents or low dose cytarabine provided unprecedented breakthrough for the frontline treatment of older, unfit AML patients. Even with all this exciting progress, more targeted therapies for AML treatment are needed. Recent development of menin inhibitors targeting AML with KMT2A rearrangements or NPM1 mutations could represent a promising new horizon of treatment for patients within these subsets of AML. Our current review will focus on a summary and updates of recent developments of menin inhibitors in the treatment of AML, on the challenges ahead arising from drug resistance, as well as on the opportunities of novel combinations with menin inhibitors.
Literature
1.
2.
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404–7.PubMedCrossRef
3.
Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, Pugeat M. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Human Molecul Gene. 1997;6(7):1177–83.CrossRef
4.
5.
6.
7.
Yokoyama A. Transcriptional activation by MLL fusion proteins in leukemogenesis. Exp Hematol. 2017;1(46):21–30.CrossRef
8.
9.
10.
11.
Schneider R, Bannister AJ, Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci. 2002;27(8):396–402.PubMedCrossRef
12.
Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207–18.PubMedCrossRef
13.
14.
15.
16.
Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, Wen Y. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615(7954):913–9.PubMedPubMedCentralCrossRef
17.
Wenge DV, Armstrong SA. The future of HOXA-expressing leukemias: menin inhibitor response and resistance. Current Opin Hematol. 2024;31(2):64–70.
18.
Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899–902.PubMedCrossRef
19.
Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, Shurtleff SA, Downing JR. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia. 2007;21(9):2000–9.PubMedCrossRef
20.
Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P. Both carboxy-terminus NES motif and mutated tryptophan (s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107(11):4514–23.PubMedCrossRef
21.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–66.PubMedCrossRef
22.
Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R, Martelli MP, Liso A, Mecucci C, Fabbiano F, Martelli MF. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res. 2007;67(13):6230–7.PubMedCrossRef
23.
Dovey OM, Cooper JL, Mupo A, Grove CS, Lynn C, Conte N, Andrews RM, Pacharne S, Tzelepis K, Vijayabaskar MS, Green P. Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia. Blood J Am Soc Hematol. 2017;130(17):1911–22.
24.
Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL. Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018;34(3):499–512.PubMedPubMedCentralCrossRef
25.
Kühn MWM, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6(10):1166–81.PubMedPubMedCentralCrossRef
26.
27.
Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34(3):499-512.e9.PubMedPubMedCentralCrossRef
28.
Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36(6):660-673.e11.PubMedPubMedCentralCrossRef
29.
30.
HJ Super NMMTRLMBJPB. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993;82(12):3705–11.CrossRef
31.
Winters AC, Bernt KM. MLL-rearranged leukemias—an update on science and clinical approaches. Front Pediatrics. 2017;9(5):4.
32.
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood J Am Soc Hematol. 2017;129(4):424–47.
33.
Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102(7):2395–402.PubMedCrossRef
34.
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood J Am Soc Hematol. 2010;115(3):453–74.
35.
Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MD, Barbieri BC. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32(2):273–84.PubMedCrossRef
36.
37.
Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 2007;67(15):7275–83.PubMedPubMedCentralCrossRef
38.
Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood J Am Soc Hematol. 2020;136(15):1707–21.
39.
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clinical Oncol. 2010;28(4):596–604.CrossRef
40.
Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, et al. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica. 2014;99(8):1317–25.PubMedPubMedCentralCrossRef
41.
Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood J Am Soc Hematol. 2008;111(5):2776–84.
42.
Uckelmann HJ, Haarer EL, Takeda R, Wong EM, Hatton C, Marinaccio C, et al. Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. Cancer Discov. 2023;13(3):746–65.PubMedPubMedCentralCrossRef
43.
Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482–95.PubMedCrossRef
44.
Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022;12(1):5.PubMedPubMedCentralCrossRef
45.
Abuhantash M, Collins EM, Thompson A. Role of the HOXA cluster in HSC emergence and blood cancer. Biochem Soc Trans. 2021;49(4):1817–27.PubMedCrossRef
46.
Issa GC, Aldoss I, DiPersio JF, Cuglievan B, Stone RM, Arellano ML, Thirman MJ, Patel MR, Dickens D, Shenoy S, Shukla N. The Menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: updated results of a phase (Ph) 1 study. Blood. 2022;140(1):150–2.CrossRef
47.
Aldoss I, Issa GC, Thirman M, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E. Revumenib Monotherapy in patients with relapsed/refractory KMT2Ar Acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study. Blood. 2023;21(142):5.CrossRef
48.
Zucenka A, Issa GC, Arellano M, Khazal S, Khera N, Stock W, Cuglievan B, Gu Y, Van Nguyen H, Smith AR, Stein EM. Revumenib maintenance therapy following revumenib-induced remission and transplant. Blood. 2023;28(142):4950.CrossRef
49.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022;36(11):2729–33.PubMedPubMedCentralCrossRef
50.
Burrows F, Wu T, Kessler L, Li S, Zhang J, Zarrinkar P, Li L, Cierpicki T, Grembecka J, Ren P, Liu Y. Abstract LB-A27: a novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML. Molecul Cancer Therapeut. 2018;1(17):27.CrossRef
51.
Erba HP, Fathi AT, Issa GC, Altman JK, Montesinos P, Patnaik MM, Foran JM, De Botton S, Baer MR, Schiller GJ, Walter RB. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022;140(1):153–6.CrossRef
52.
Wang ES, Altman JK, Pettit K, De Botton S, Walter RP, Fenaux P, Burrows F, Tomkinson BE, Martell B, Fathi AT. Preliminary data on a phase 1/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia. Blood. 2020;5(136):7–8.CrossRef
53.
Title: CLINICAL pharmacology and pharmacokinetic profile of ziftomenib, a menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia.
54.
Cierpicki T, Grembecka J. Challenges and opportunities in targeting the menin-MLL interaction. Future Med Chem. 2014;6(4):447–62.PubMedCrossRef
55.
Eguchi K, Shimizu T, Kato D, Furuta Y, Kamioka S, Ban H, Ymamoto S, Yokoyama A, Kitabayashi I. Preclinical Evaluation of a novel orally bioavailable menin-MLL interaction inhibitor, DSP-5336, for the Treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation. Blood. 2021;23(138):3339.CrossRef
56.
Daver N, Zeidner JF, Yuda J, Watts JM, Levis MJ, Fukushima K, Ikezoe T, Ogawa Y, Brandwein J, Wang ES, Miyazaki Y. Phase 1/2 First-in-human study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia. Blood. 2023;28(142):2911.CrossRef
57.
58.
Kwon MC, Querolle O, Dai X, Thuring JW, Verhulst T, Marien A, Goffin D, Cai W, Keersmaekers V, Eyassu F, Verstraeten K. Pharmacological characterization of JNJ-75276617, a menin-KMT2A inhibitor, as targeted treatment for KMT2A-altered and NPM1-mutant acute leukemia. Blood. 2022;140(1):5928–9.CrossRef
59.
Jabbour E, Searle E, Abdul-Hay M, Abedin S, Aldoss I, Piérola AA, Alonso-Dominguez JM, Chevallier P, Cost C, Daskalakis N, Dillon R. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations. Blood. 2023;28(142):57.CrossRef
60.
Wei A, et al. A phase 1b study of the menin-kmt2a inhibitor jnj-75276617 in combination with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia with alterations in kmt2a or nPM1. Europ Hematol Associat. 2024;5(14):24.
61.
Numata M, Haginoya N, Shiroishi M, Hirata T, Sato-Otsubo A, Yoshikawa K, Takata Y, Nagase R, Kashimoto Y, Suzuki M, Schulte N. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. Cancer Cell Int. 2023;23(1):36.PubMedPubMedCentralCrossRef
62.
Lourenco C, Resetca D, Redel C, Lin P, MacDonald AS, Ciaccio R, Kenney TM, Wei Y, Andrews DW, Sunnerhagen M, Arrowsmith CH. MYC protein interactors in gene transcription and cancer. Nature Rev Cancer. 2021;21(9):579–91.CrossRef
63.
Lancet J, Ravandi F, Montesinos P, Barrientos JC, Badar T, Alegre A, Bashey A, Burgues JM, Brunetti L, Curran EK, de Leeuw DC. Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R/R) acute leukemia (AL): preliminary phase 1 data from the covalent-101 study. Blood. 2023;28(142):2916.CrossRef
64.
Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2(13):1645–50.PubMedPubMedCentralCrossRef
65.
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96.PubMedPubMedCentralCrossRef
66.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JE. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571–83.PubMedCrossRef
67.
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England J Med. 2017;377(5):454–64.CrossRef
68.
Jentzsch M, Grimm J, Bill M, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. Outcomes of older patients with NPM1 mutated and FLT3-ITD negative acute myeloid leukemia receiving allogeneic transplantation. HemaSphere. 2020;4(1): e326.PubMedPubMedCentralCrossRef
69.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020;4(7):1311–20.PubMedPubMedCentralCrossRef
70.
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute Myelogenous Leukemia. Cancer Discov. 2016;6(10):1106–17.PubMedPubMedCentralCrossRef
71.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–45.PubMedPubMedCentralCrossRef
72.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. New England J Med. 2020;383(7):617–29.CrossRef
73.
Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica. 2023;108(10):2837.PubMedPubMedCentralCrossRef
74.
75.
Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 20020808th ed. 2002;100(13):4372–80.
76.
Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood J Am Soc Hematol. 2007;110(4):1262–70.
77.
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England J Med. 2017;377(5):454–64.CrossRef
78.
Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. 2022;36(9):2218–27.PubMedPubMedCentralCrossRef
79.
Bill M, Mrózek K, Kohlschmidt J, Eisfeld AK, Walker CJ, Nicolet D, Papaioannou D, Blachly JS, Orwick S, Carroll AJ, Kolitz JE. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proceed National Academy Sci. 2020;117(42):26340–6.CrossRef
80.
Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020;136(21):2442–56.PubMedPubMedCentralCrossRef
81.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920–4.PubMedPubMedCentralCrossRef
82.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66–78.PubMedPubMedCentralCrossRef
83.
Dafflon C, Craig VJ, Mereau H, Gräsel J, Schacher Engstler B, Hoffman G, Nigsch F, Gaulis S, Barys L, Ito M, Aguadé-Gorgorió J. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia. 2017;31(6):1269–77.PubMedCrossRef
84.
Chen CW, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Experimental Hematol. 2015;43(8):673–84.CrossRef
85.
Dafflon C, Craig VJ, Mereau H, Gräsel J, Schacher Engstler B, Hoffman G, Nigsch F, Gaulis S, Barys L, Ito M, Aguadé-Gorgorió J. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia. 2017;31(6):1269–77.PubMedCrossRef
86.
Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clinic Investigat. 2016;126(4):1438–50.CrossRef
87.
Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, Waters NJ. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood J Am Soc Hematol. 2013;122(6):1017–25.
88.
Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood J Am Soc Hematol. 2018;131(24):2661–9.
89.
Perner F, Gadrey JY, Xiong Y, Hatton C, Eschle BK, Weiss A, Stauffer F, Gaul C, Tiedt R, Perry JA, Armstrong SA. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood J Am Soc Hematol. 2020;136(17):1983–8.
90.
Uddin MH, Aboukameel A, Khan H, Bannoura S, Deol A, Yang J, Dyson G, Azmi A, Polin L, Maciejewski JP, Balasubramanian SK. The clinical menin inhibitor ziftomenib and the nuclear export inhibitor selinexor synergistically inhibit the growth of MLL-r AML. Blood. 2023;142(1):4168.CrossRef
91.
Pianigiani G, Gagliardi A, Mezzasoma F, Rocchio F, Tini V, Bigerna B, Sportoletti P, Caruso S, Marra A, Peruzzi S, Petito E. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML. Blood Adv. 2022;6(22):5938–49.PubMedPubMedCentralCrossRef
92.
Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nature Cell Biol. 2007;9(7):804–12.PubMedCrossRef
93.
Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood J Am Soc Hematol. 2022;139(6):894–906.
94.
Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ. NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis. Cancer Cell. 2016;30(6):863–78.PubMedPubMedCentralCrossRef
95.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O. The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML. Hemasphere. 2023;7(8): e935.PubMedPubMedCentralCrossRef
96.
Michmerhuizen NL, Klco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood J Am Soc Hematol. 2020;136(20):2275–89.
97.
Liu H. NUP98 rearrangement in B lymphoblastic leukemia with hyperdiploidy. Blood J Am Soc Hematol. 2020;136(8):1011.
98.
Lauw MI, Qi Z, Eversmeyer L, Prakash S, Wen KW, Yu J, Monaghan SA, Aggarwal N, Wang L. Distinct pathologic feature of myeloid neoplasm with t (v; 11p15); NUP98 rearrangement. Human Pathol. 2022;1(123):11–9.CrossRef
99.
Lim HH, An GD, Woo KS, Kim KH, Kim JM, Kim SH, Han JY. NUP98 rearrangement in acute myelomonocytic leukemia with t (11; 19)(p15; p12): the first case report worldwide. Annal Laborat Med. 2017;37(3):285.CrossRef
100.
Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N, Talmant P, Bilhou-Nabera C, Mugneret F, Lafage-Pochitaloff M, Mozziconacci MJ. NUP98 rearrangements in hematopoietic malignancies: a study of the groupe francophone de cytogenetique hematologique. Leukemia. 2006;20(4):696–706.PubMedCrossRef
101.
Xie W, Raess PW, Dunlap J, Hoyos CM, Li H, Li P, Swords R, Olson SB, Yang F, Anekpuritanang T, Hu S. Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome. Leukemia Lymphoma. 2022;63(8):1907–16.PubMedCrossRef
102.
Bertrums EJ, Smith JL, Harmon L, Ries RE, Wang YC, Alonzo TA, Menssen AJ, Chisholm KM, Leonti AR, Tarlock K, Ostronoff F. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108(8):2044.PubMedPubMedCentralCrossRef
103.
Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ. NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis. Cancer Cell. 2016;30(6):863–78.PubMedPubMedCentralCrossRef
104.
Potluri S, Kellaway SG, Coleman DJ, Keane P, Imperato MR, Assi SA, Cockerill PN, Bonifer C. Gene regulation in t (6; 9) DEK: NUP214 acute myeloid leukemia resembles that of FLT3-ITD/NPM1 acute myeloid leukemia but with an altered HOX/MEIS axis. Leukemia. 2024;38(2):403–7.PubMedPubMedCentralCrossRef
105.
Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, Cayuela JM, Chilton L. t (6; 9)(p22; q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica. 2014;99(5):865.PubMedPubMedCentralCrossRef
106.
107.
108.
109.
Barajas J, Umeda M, Ma J, Khanlari M, Walsh MP, Westover T, Contreras L, Song G, Ma X, Thomas M III, Klco JM. UBTF tandem duplications in pediatric MDS and AML: implications for clinical screening and diagnosis. Blood. 2023;28(142):838.CrossRef
110.
Barajas JM, Rasouli M, Umeda M, Hiltenbrand R, Abdelhamed S, Mohnani R, Arthur B, Westover T, Thomas ME III, Ashtiani M, Janke LJ. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. Blood. 2024;143(7):619–30.PubMedCrossRef
111.
Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, Perlee S, Perner F, Rahnamoun H, Theall AC, Henrich JA. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nature Cancer. 2022;3(5):595–613.PubMedPubMedCentralCrossRef
112.
Bourgeois W, Cutler JA, Aubrey BJ, Wenge DV, Perner F, Martucci C, Henrich JA, Klega K, Nowak RP, Donovan KA, Boileau M. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. Blood. 2024;143(15):1513–27.PubMedCrossRef
Metadata
Title
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead
Authors
Kalyan V. G. Nadiminti
Kieran D. Sahasrabudhe
Hongtao Liu
Publication date
18-11-2024
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2024
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-024-01632-8

Other articles of this Issue 1/2024

SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing

  • Open Access
  • SCLC
  • Research

Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms

Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant

  • Open Access
  • Research

Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation

  • Open Access
  • Research

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

  • Open Access
  • Review

Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits